Summary by Moomoo AI
Aclarion, Inc., a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) to optimize clinical treatments, reported financial results for the year ended December 31, 2023. The company experienced a net loss of $4,911,374, a decrease from the previous year's net loss of $7,068,593. Total revenue increased slightly to $75,404, up from $60,444 in 2022, primarily due to increased utilization of Nociscan in clinical studies. Operating expenses decreased by $681,057 to $4,875,657, with sales and marketing expenses rising by $259,001 due to increased restricted stock units for Key Opinion Leaders. Research and development expenses decreased by $194,656, and general and administrative expenses saw a reduction of $745,402. Interest expense also decreased by $899,258 due to the absence of a beneficial conversion rate charged in 2022. The company's cash position at year-end...Show More